

## 学术搜索

找到约 3,350 条结果 (用时0.13秒)

## 文章

## 我的图书馆

## 时间不限

2015以来

2014以来

2011以来

自定义范围...

## 按相关性排序

## 按日期排序

## 搜索所有网页

中文网页

英语网页

☒ 包括专利☒ 包含引用☐ 创建快讯**Monoclonal antibody therapy of cancer**

GP Adams, LM Weiner - Nature biotechnology, 2005 - nature.com

... antibody responses; such events could be viewed as 'footprints' and potential biomarkers of ADCC ...

Treatment with rituximab can cause a profound first-dose toxicity related to the rapid ... Cetuximab

therapy, directed against EGFR, causes a significant skin eruption that is based on ...

被引用次数: 916 相关文章 所有 10 个版本 引用 保存

purdue.edu 中的 [PDF]

**Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer**

S Siena, A Sartore-Bianchi... - ... the National Cancer ..., 2009 - jnci.oxfordjournals.org

... However, increased toxicity and a shorter progression-free interval were observed in the ... Although

most biomarker datasets are from chemotherapy-refractory or relapsed patients who ... KRAS

mutations have been explored as prognostic biomarkers (independent of anti-EGFR ...

被引用次数: 411 相关文章 所有 13 个版本 引用 保存

oxfordjournals.org 中的 [HTML]

**A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor**

F Ciardiello, G Tortora - Clinical Cancer Research, 2001 - AACR

... Skin toxicities were mainly flushing or acneiform rashes, ... 7%). In this study, IMC-C225 treatment

was well tolerated and did not increase the toxicity attributable to ... and dose-dependent decrease

in c-fos mRNA, which can be considered a downstream nuclear biomarker for EGFR ...

被引用次数: 1020 相关文章 所有 6 个版本 引用 保存

aacrjournals.org 中的 [HTML]

**... randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer**

JR Hecht, E Mitchell, T Chidiac... - Journal of Clinical ..., 2009 - jco.ascopubs.org

... the updated analysis are summarized (Table 4). As expected, skin-related toxicities were the ...

Yvonne Denkins, PhD, for study management; Sam Suzuki, MS, for KRAS biomarker analyses;

Feng ... Updated results of STEPP, a phase 2, open-label study of skin toxicity evaluation in ...

被引用次数: 665 相关文章 所有 7 个版本 引用 保存

gnmhealthcare.com 中的 [PDF]

**... for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival**

JA Bonner, PM Harari, J Giralt, RB Cohen, CU Jones... - The lancet oncology, 2010 - Elsevier

... Mitigating toxicity remains an important goal in developing new treatment approaches for patients

with LASCCHN. ... 34 Information regarding late toxicities was not collected. ... In a previous publication,

25 pustular rash and dry skin were included, but further review with the ...

被引用次数: 870 相关文章 所有 12 个版本 引用 保存

elsevier-eprints.com 中的 [PDF]

**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 20131

**Manuscript Type:** Minireviews

**Biomarkers of skin toxicity induced by anti-EGFR antibody treatment in colorectal cancer**

Kubo A *et al.* Skin toxicity of anti-EGFR antibody

Akiko Kubo, Hironobu Hashimoto, Naoki Takahashi, Yasuhide Yamada

**Akiko Kubo, Hironobu Hashimoto**, Division of pharmacy, National Cancer Center Hospital, Tokyo 104-0045, Japan

**Naoki Takahashi, Yasuhide Yamada**, Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo 104-0045, Japan

**Author contributions:** Kubo A and Hashimoto H contributed equally to this

## Match Overview

1	<b>Internet</b> 127 words crawled on 01-Jul-2015 <a href="http://www.wjgnet.com">www.wjgnet.com</a>	2%
2	<b>CrossCheck</b> 35 words Baas, J.M.. "Recommendations on management of EGFR ... inhibitor-induced skin toxicity: A systematic review", <i>Cancer</i>	1%
3	<b>CrossCheck</b> 26 words Yevgeniy Balagula. "Clinical presentation and management of dermatological toxicities of epidermal growth factor rece	<1%
4	<b>Internet</b> 23 words crawled on 12-Sep-2013 <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a>	<1%
5	<b>CrossCheck</b> 23 words Takahashi, Naoki, Yasuhide Yamada, Koh Furuta, Kengo N agashima, Akiko Kubo, Yusuke Sasaki, Hirokazu Shoji, Yos	<1%



学术搜索

找到约 3,620 条结果 (用时0.03秒)

文章

我的图书馆

时间不限

2015以来

2014以来

2011以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

简体中文网页

☒ 包括专利

☒ 包含引用

☐ 创建快讯

小提示: 只搜索中文(简体)结果, 可在 学术搜索设置 指定搜索语言

### Monoclonal antibody therapy of cancer

GP Adams, LM Weiner - Nature biotechnology, 2005 - nature.com

... antibody responses; such events could be viewed as 'footprints' and potential biomarkers of ADCC ...

Treatment with rituximab can cause a profound first-dose toxicity related to the rapid ... Cetuximab

therapy, directed against EGFR, causes a significant skin eruption that is based on ...

被引用次数: 956 相关文章 所有 11 个版本 引用 保存

nature.com 中的 [HTML]

### Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

S Siena, A Sartore-Bianchi... - ... the National Cancer ..., 2009 - jnci.oxfordjournals.org

... However, increased toxicity and a shorter progression-free interval were observed in the ... Although

most biomarker datasets are from chemotherapy-refractory or relapsed patients who ... KRAS

mutations have been explored as prognostic biomarkers (independent of anti-EGFR ...

被引用次数: 438 相关文章 所有 12 个版本 引用 保存

### A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor

F Ciardiello, G Tortora - Clinical Cancer Research, 2001 - AACR

... Skin toxicities were mainly flushing or acneiform rashes. .... 7%). In this study, IMC-C225 treatment

was well tolerated and did not increase the toxicity attributable to ... and dose-dependent decrease

in c-fos mRNA, which can be considered a downstream nuclear biomarker for EGFR ...

被引用次数: 1037 相关文章 所有 6 个版本 引用 保存

aacrjournals.org 中的 [HTML]

### ... for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

JA Bonner, PM Harari, J Giral, RB Cohen, CU Jones... - The lancet oncology, 2010 - Elsevier

... Mitigating toxicity remains an important goal in developing new treatment approaches for patients

with LASCCHN. ... 34 Information regarding late toxicities was not collected. ... In a previous publication,

25 pustular rash and dry skin were included, but further review with the ...

被引用次数: 934 相关文章 所有 14 个版本 引用 保存

researchgate.net 中的 [PDF]

### ... randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

JR Hecht, E Mitchell, T Chidiac... - Journal of Clinical ..., 2009 - jco.ascopubs.org

... id, skin-related toxicities were the ... inferior

gnmhealthcare.com 中的 [PDF]

[网页](#) [图片](#) [新闻](#) [视频](#) [购物](#) [更多 ▾](#) [搜索工具](#)

找到约 367,000 条结果 (用时 0.66 秒)

## Google 学术 : Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer

... cancer: targeting the epidermal growth factor receptor - Ciardiello - 被引用次数 : 1039

... of epidermal growth factor receptor-targeted therapy ... - Siena - 被引用次数 : 439

... factor receptor antagonists in the biology and treatment ... - Mendelsohn - 被引用次数 : 1292

### Targeting colorectal cancer with anti-epidermal growth ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > ... > PubMed Central (PMC) ▾ [翻译此页](#)

作者 : D Hoda - 2008 - 被引用次数 : 17 - [相关文章](#)

Further studies with panitumumab will be required to develop biomarkers of ... Murine antibodies targeting EGFR, both agonist and antagonist, were ... mechanism of activity of monoclonal anti-EGFR therapy (Cocker et al 1994; Ewald .... The management of the skin toxicity is largely empiric and supportive (Fox et al 2006).

### Anti-epidermal growth factor receptor monoclonal ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > ... > PubMed Central (PMC) ▾ [翻译此页](#)

作者 : E Martinelli - 2009 - 被引用次数 : 123 - [相关文章](#)

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy ... of metastatic colorectal and head and neck cancer which target the external part of EGFR. .... The incidence of skin toxicity in the panitumumab group was dose-related; ... B1 (BRAF) as a potential biomarker for anti-EGFR antibody treatment.